Durham, NC, United States · North America
100sterile
OncologyRare diseaseCell & gene therapyVaccines
FDAEMAPMDANMPA
SCALE 270 studies
Loading…
Clinical Development
CROs
Clinical research organizations38
CROs listed
Trial management, monitoring, biostatistics and data services — scored on real operational depth, not sales polish.
Scores are deterministic, rules-based — not AI.
OncologyCell & gene therapyRare diseaseVaccines
NMPAFDAEMAPMDA
SCALE 270 studies
OncologyCell & gene therapyRare disease
NMPAFDA
SCALE 190 studies
Rare diseaseOncologyCell & gene therapy
FDAEMAPMDAMHRA
SCALE 270 studies
OncologyVaccinesRare disease
NMPAFDAEMAPMDA
SCALE 270 studies
Oncology
FDAEMAPMDANMPA
SCALE 270 studies
OncologyVaccines
PMDAFDAEMANMPA
SCALE 270 studies
OncologyRare disease
FDAEMAMHRA
SCALE 260 studies
OncologyInfectious diseaseVaccines
FDAEMAMHRAHealth Canada
SCALE 270 studies
OncologyRare disease
FDAEMAMHRA
SCALE 270 studies
OncologyCell & gene therapy
NMPAFDAEMAMHRA
SCALE 270 studies
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 270 studies
OncologyRare disease
PMDAFDAEMANMPA
SCALE 270 studies
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 270 studies
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 230 studies
Not stated as a therapeutic-area list. The company names immuno-oncology and T-cell biology as biologics/discovery focus areas; its offering is otherwise described by modality (small moleculespeptidesoligonucleotidesmAbs
FDA
SCALE 00 studies
Oncology
EMAFDAMHRA
SCALE 240 studies
Oncology
PMDANMPAFDA
SCALE 260 studies
Oncology
FDANMPA
SCALE 220 studies
FDAPMDA
SCALE 00 studies
Oncology
PMDAFDA
SCALE 120 studies
FDAPMDA
SCALE 00 studies
NMPAFDAEMA
SCALE 20 studies